Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.13.11.33: arachidonate 15-lipoxygenase

This is an abbreviated version!
For detailed information about arachidonate 15-lipoxygenase, go to the full flat file.

Word Map on EC 1.13.11.33

Reaction

arachidonate
+
O2
=
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate

Synonyms

12/15 lipoxygenase, 12/15 Lox, 12/15-lipoxygenase, 12/15-LO, 12/15-LOX, 12/15LO, 15(S)-lipoxygenase-1, 15-hLO, 15-hLO-1, 15-hLO-2, 15-lipoxygenase, 15-lipoxygenase 1, 15-lipoxygenase 2, 15-lipoxygenase type 1, 15-lipoxygenase type 2, 15-lipoxygenase type-1, 15-lipoxygenase-1, 15-lipoxygenase-2, 15-lipoxygenase-I, 15-LO, 15-LO-1, 15-LO-2, 15-LO-I, 15-LOX, 15-LOX type 1, 15-LOX-1, 15-LOX-2, 15-LOX-A, 15-LOX2, 15-rLO, 15-rLO-1, 15-sLO, 15LO1, 15S-lipoxygenase, 15S-LOX1, ALOX12, Alox15, ALOX15-2, ALOX15B, arachidonate 12/15-lipoxygenase, arachidonate 15-lipoxygenase, arachidonate 15-lipoxygenase-1, arachidonic acid 15-lipoxygenase, arachidonic acid 15-lipoxygenase-1, cardiac 12/15-LOX, endothelial 15-lipoxygenase-1, epidermis-type 15-LOX, human prostate epithelial 15-lipoxygenase-2, linoleic acid omega-6-lipoxygenase, lipoxygenase L-1, lipoxygenase-1, LO-1, LOX-1, LOX2, LOX2:Hv:1, LoxA, More, omega-6 lipoxygenase, oxygenase, arachidonate 15-lip-, reticulocyte 15-lipoxygenase-1, reticulocyte 15-LOX, reticulocyte-type 15-human lipoxygenase, reticulocyte-type 15-lipoxygenase, reticulocyte-type 15-LO-1, reticulocyte-type of 15-LOX-1, SLO, soybean 15-lipoxygenase, soybean lipoxygenase-3

ECTree

     1 Oxidoreductases
         1.13 Acting on single donors with incorporation of molecular oxygen (oxygenases)
             1.13.11 With incorporation of two atoms of oxygen
                1.13.11.33 arachidonate 15-lipoxygenase

Inhibitors

Inhibitors on EC 1.13.11.33 - arachidonate 15-lipoxygenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-5,7-O-diacetyl-3',4',5'-O-triacetylepigallocatechin-3-O-(3'',4'',5''-O-triacetyl)gallate
-
IC50: 0.061 mM
(-)-5,7-O-dibutyryl-3',4',5'-O-tributyrylepigallocatechin-3-O-(3'',4'',5''-O-tributyryl) gallate
-
IC50: 0.033 mM
(-)-5,7-O-dimethyl-3',4',5'-O-trimethylepigallocatechin-3-O-(3'',4'',5''-O-trimethyl) gallate
-
IC50: 0.03 mM
(-)-5,7-O-dipropionyl-3',4',5'-O-tripropionylepigallocatechin-3-O-(3'',4'',5''-O-tripropionyl) gallate
-
IC50: 0.031 mM
(-)-epigallocatechin-3-gallate
-
IC50: 0.1 mM
(-)-jaspic acid
-
IC50: 0.0014 mM
(Z)-9-octadecenyl sulfate
-
allosteric inhibition
1,2,3-triphenylindolizine-7-carbonitrile
-
IC50: 0.028 mM
1-(((2,4,6-trimethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.017 mM
1-(((2,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.027 mM
1-(((2,5-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.015 mM
1-(((2-methyl)ethylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.042 mM
1-(((2-methyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((2-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.021 mM
1-(((3,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.019 mM
1-(((3-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-(((4-(2-methylethyl)phenl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.016 mM
1-(((4-chlorophenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.22 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-dibutyl-7-indolizinecarbonitrile
-
IC50: 0.03 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diethyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarboxaldehyde
-
IC50: 0.02 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinylethanone
-
IC50: 0.023 mM
1-(((4-methysulfonyllphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-trifluoromethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-((4-methylphenyl)sulfonyl)2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-((butylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.028 mM
1-((methylsulfonyl)oxy)-2,3-diphenyl-7-indolizine-carbonitrile
-
IC50: 0.022 mM
1-((N,N-dimethylaminosulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-((phenylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(1,3-dibenzyloxy-2-propyloxy)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(1-Hydroxy-1-phenyl-ethyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
1-(1-hydroxyethyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.026 mM
1-(2-furyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.024 mM
1-(2-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.02 mM
1-(2-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(3-chlorobenzoyl)-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-(3-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(3-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.02 mM
1-(4-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(4-fluorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.035 mM
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
1-(4-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.032 mM
1-(4-methylphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.037 mM
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
-
1-(Cyclohexyl-hydroxy-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-(Hydroxy-p-tolyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.022 mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
1-(hydroxymethyl)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.026 mM
1-(hydroxymethyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.034 mM
1-(Methoxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.021 mM
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
1-acetyl-N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
1-benzyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.027 mM
1-benzyl-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
1-formyl-2,3-diphenylindolizine-7-carbonitrile
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
1-methyl-2,3-diphenylindolizine-7-carbonitrile
1-phenyl-2-([[4-(trifluoromethyl)phenyl]methyl]sulfanyl)-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
1-phenylmethoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-[(2H-1,3-benzodioxol-5-yl)carbamothioyl]-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
1-[(4-Chloro-phenyl)-hydroxy-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
-
1-[4-[4-([[5-(3-chlorophenyl)furan-2-yl]methyl]amino)phenyl]piperazin-1-yl]ethan-1-one
-
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
-
1-[Hydroxy-(4-methoxy-phenyl)-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
11-hydroxytephrosin
-
IC50: 0.071 mM
11-thialinoleic acid
-
is a noncompetitive inhibitor of 15-lipoxygenase-1 with respect to arachidonate or linoleic acid as substrates. Presence of inhibitor does not alter the product distribution for 15-lipoxygenase-1. It does not change the regioselectivity of 15-lipoxygenase-1
12alpha-hydroxydeguelin
-
IC50: 0.018 mM
12alpha-hydroxyrotenone
-
IC50: 0.102 mM
13S-hydroperoxy-9E,11E-octadecydienoic acid
-
rapidly inactivates
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.00079 mM
2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.0022 mM
2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.033 mM
2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.03 mM
2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.027 mM
2,3-Dihydroxybenzoic acid
-
47.7% inhibition at 0.015 mM, active site binding structure
2,3-diphenyl-1-(2-thienyl)indolizine-7-carbonitrile
-
IC50: 0.02 mM
2,3-diphenyl-1-(3-thienyl)indolizine-7-carbonitrile
-
IC50: 0.019 mM
2,3-diphenyl-1-indolizinol tosylate
-
IC50: 0.025 mM
2,3-diphenylindolizine-7-carbonitrile
2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol
-
IC50: 0.01 mM
2,4-Dibromophenol
-
IC50: 0.034 mM
2,4-dihydroxybenzoic acid
-
49.9% inhibition at 0.015 mM, active site binding structure
2,5-dihydroxybenzoic acid
-
21.2% inhibition at 0.015 mM, active site binding structure
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
-
IC50: 0.005 mM
2-(1H-indol-3-yl)-N-[(4-pentylphenyl)sulfonyl]acetamide
-
-
2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
2-(4-ethylpiperazin-1-yl)4-methylpyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
-
2-alkyl benzopyran-4-ones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-alkyl-6-hydroxy-4-H-benzopyran-4-one
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-hydroxybenzoic acid
-
46.0% inhibition at 0.015 mM, active site binding structure
2-phenyl-3-[3-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-5-yl]-1H-indole
molecular docking, compound is stabilized in the catalytic pocket of enzyme by pi-cation interaction with the catalytic Fe+ and formation of one hydrogen bond with Ile 676 amino acid
-
2-[2-(1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[2-(2-bromo-1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[3-(1H-indol-3-yl)propyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethan-1-amine
-
2-[[(4-bromophenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
2-[[(4-ethylphenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
3'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
3'-naphthalen-2-yl-1'-phenyl-5-p-tolyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3,4,5-Trihydroxybenzoic acid
-
60.5% inhibition at 0.015 mM, active site binding structure
3,4,6,8-tetrabromooxanthren-1-ol
-
IC50: 0.0009 mM
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
-
IC50: 0.011 mM
3,4-dihydroxybenzoic acid
-
51.6% inhibition at 0.015 mM, active site binding structure; 73.3% inhibition at 0.015 mM, active site binding structure
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
3,5-Dihydroxybenzoic acid
-
58.1% inhibition at 0.015 mM, active site binding structure
3,6,8-tribromooxanthren-1-ol
-
IC50: 0.0008 mM
3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylic acid
-
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-cyclohexylimidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-N-cyclohexyl-6-(2-nitrophenyl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-methoxyphenyl)-5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-1,2-oxazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3-(4-methoxyphenyl)-6-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
protective activity of compound 5i against H2O2-induced cell death in differentiated PC12 cells
3-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
3-Hydroxybenzoic acid
-
47.6% inhibition at 0.015 mM, active site binding structure
3-[1-[(4-pentylphenyl)sulfonyl]pyrrolidin-3-yl]-1H-indole
-
-
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
3-[[(4-methylphenyl)methyl]sulfanyl]-1-phenyl-1H-1,2,4-triazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
4',6,7-trihydroxyisoflavan
-
-
4',6,7-trihydroxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
4',6,7-trihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4'-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00053 mM in the presence of arachidonate, IC50: 0.0002 mM in the presence of linoleic acid
4'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4'-ethyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00026 mM in the presence of arachidonate, IC50: 0.00047 mM in the presence of linoleic acid
4'-tert-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00027 mM in the presence of arachidonate, IC50: 0.00023 mM in the presence of linoleic acid
4,4'-(2,3-dimethylbutane-1,4-diyl)di(benzene-1,2-diol)
-
4,4'-propane-2,2-diylbis(2,6-dibromophenol)
-
IC50: 0.004 mM
4,5-bis(4-chlorophenyl)-1H-imidazole-2-thiol
-
-
4,5-bis(4-fluorophenyl)-1H-imidazole-2-thiol
-
-
4,5-bis(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
4,5-diphenyl-1H-imidazole-2-thiol
-
-
4,7,10,13-eicosatetraenoic acid
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate
-
-
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
-
4-(2-benzoylhydrazinyl)benzene-1-sulfonamide
10% inhibition
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(4-chlorophenyl)-5-phenyl-1H-imidazole-2-thiol
-
-
4-(4-methoxyphenyl)-5-phenyl-1H-imidazole-2-thiol
-
-
4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-hydroxynaphthalen-2-yl)-1,3,4-oxadiazol-2-ylthio)-but-2-ynyl-4-fluorobenzoate
-
low solubility
4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-thiadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
low solubility
4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(3-hydroxypropyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(4-methoxyphenyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-butylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-cyclohexylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-phenylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-[3-(dimethylamino)propyl]benzamide
-
-
4-([2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]sulfamoyl)benzoic acid
-
-
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
4-allyl-2-methoxyphenyl 2-chlorobenzoate
4-allyl-2-methoxyphenyl 2-fluorobenzoate
4-allyl-2-methoxyphenyl 2-methylbenzoate
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
4-allyl-2-methoxyphenyl 3-chlorobenzoate
4-allyl-2-methoxyphenyl 3-fluorobenzoate
4-allyl-2-methoxyphenyl 3-methoxybenzoate
4-allyl-2-methoxyphenyl 3-methylbenzoate
4-allyl-2-methoxyphenyl 4-chlorobenzoate
4-allyl-2-methoxyphenyl 4-fluorobenzoate
4-allyl-2-methoxyphenyl 4-methoxybenzoate
4-allyl-2-methoxyphenyl 4-methylbenzoate
4-allyl-2-methoxyphenyl benzoate
4-allyl-2-methoxyphenyl isonicotinate
4-allyl-2-methoxyphenyl nicotinate
4-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-Bromophenol
4-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-butyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.00307 mM in the presence of arachidonate, IC50: 0.004 mM in the presence of linoleic acid
4-butyl-N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chlorophenyl 3-[(2-chlorophenyl)carbamoyl]-1H-pyrazole-1-carboxylate
-
4-ethyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
4-hydroxy-3-methoxybenzoic acid
-
45.4% inhibition at 0.015 mM, active site binding structure
4-hydroxybenzoic acid
-
47.0% inhibition at 0.015 mM, active site binding structure
4-methyl-2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-hydroxypiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine
-
-
4-methyl-2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-nitrocatechol
-
IC50: 0.0046 mM
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-(2-[2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-[2-(2-phenyl-1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(2-quinolin-3-yl-1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-[5-(1H-pyrrol-2-yl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
-
-
4-[(E)-benzoyldiazenyl]benzene-1-sulfonamide
-
4-[(E)-benzoyldiazenyl]benzonitrile
80% inhibition, competitive
4-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
4-[4-(methylsulfanyl)phenyl]-5-phenyl-1H-imidazole-2-thiol
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
-
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
-
5,8,11,14,17-eicosapentaenoic acid
5,8,11,14-eicosatetraenoic acid
5,8,11,14-Eicosatetraynoic acid
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-1'-phenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-2,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']-bipyrazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-3-p-tolyl-4,5-dihydro-1,2-oxazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-(methylsulfanyl)-1H-imidazole
-
-
5-(4-chlorophenyl)-4-[4-(dimethylamino)phenyl]-1H-imidazole-2-thiol
-
-
5-(4-chlorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
-
-
5-(4-fluorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
5-(4-fluorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
-
-
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
5-(methylamino)-2-(naphthalen-1-yl)-4,5-dihydro-1,3-oxazole-4-carbonitrile
-
-
5-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-butyl-N3-(2-chloro-4-fluorophenyl)-N1-hexyl-1H-pyrazole-1,3-dicarboxamide
-
5-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-chloro-N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
-
5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-ethoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.028 mM
5-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
5-tert-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
6,11-dihydro[1]benzothiopyrano[4,3-b]indole
-
PD146176
6,6a,11,11a-tetrahydro[1]benzothiopyrano[4,3-b]indole
-
-
6,7-dihydroxy-2-t-butylbenzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-4'-methoxyisoflavan
-
-
6,7-dihydroxy-4'-methoxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxyisoflavones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
6,7-dimethoxy-2,3-dihydrochromone
-
IC50: 0.137 mM
6,7-diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate
-
IC50: 0.015 mM
6,7-diphenylpyrrolo[1,2-b]pyridazin-5-yl trifluoromethanesulfonate
-
IC50: 0.043 mM
6,7-diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate
-
IC50: 0.022 mM
6-(2-bromophenyl)-N-cyclohexyl-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
6-(2-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-(4-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(4,5-dichloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(5-chloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-hydroxy-2-pentyl-4H-benzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6-oxo-6alpha,12alpha-dehydrodeguelin
-
-
6-[4-([1,1'-biphenyl]-2-yl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
-
6-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-phenylhexan-1-one
-
low solubility
6alpha,12alpha-12alpha-hydroxyelliptone
-
IC50: 0.062 mM
6alpha,12alpha-dehydrodeguelin
-
IC50: 0.071 mM
7,10,13-eicosatrienoic acid
7,8-dihydroxy-3',4'-dimethoxyisoflavan
-
-
7,8-dihydroxy-3'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-3'-trifluoromethylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-4'-methoxyisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
7-(1,1-dimethylethyl)-2,3-diphenyl-1-indolizinol tosylate
-
IC50: 0.022 mM
7-cyano-2,3-diphenylindolizin-1-yl 2-methoxybenzoate
-
IC50: 0.03 mM
7-cyano-2,3-diphenylindolizin-1-yl 3-methoxybenzoate
-
IC50: 0.028 mM
7-cyano-2,3-diphenylindolizin-1-yl 4-methoxybenzoate
-
IC50: 0.028 mM
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
7-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
8,11,14-eicosatrienoic acid
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
-
AA-861
AAAKKAAK
-
64.2% inhibition at 0.25 mM
adamantyl caffeate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.074 mM
-
alpha-mangostin
-
NSC30552, a natural product, caspase-3 pathway inhibitor, performs selective inhibition of 12-LO
anthraquinone
-
-
apigenin
arachidonic acid
-
autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations
baicalein
barbigerone
-
IC50: 0.063 mM
benzoic acid
-
48.4% inhibition at 0.015 mM, active site binding structure
bestatin
-
IC50: 0.027 mM
bestatin 7
-
IC50: 0.027 mM
beta-casein
-
11.7% inhibition at 0.025 mM
-
BODIPY-D3825
bornyl vanillate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.401 mM
-
caffeic acid
chrysin
-
IC50: 1 mM
cinnamyl 3,4-dihydroxy-cyanocinnamate
-
CDC
cinnamyl-3,4-dihydroxy-a-cyanocinnamate
-
-
cinnamyl-3,4-dihydroxy-cyanocinnamate
-
conjugated linoleic acids
-
conjugated linoleic acids may function as inhibitors of 15-LO-1 activity in macrophages/in vivo, overview
-
daidzein
dansyl tryptamine
-
IC50: 0.00373 mM
decyl gallate
-
-
dysidenin
-
-
ebselen
eicosatetraynoic acid
-
-
epicatechin
-
IC50: 0.06 mM
esculetin
-
-
ethyl 6-([3-[(2-chloro-4-fluorophenyl)carbamoyl]-1H-pyrazole-1-carbonyl]amino)hexanoate
-
ethyl 6-chloro-3-[(3S)-3-hydroxy-7-methyloctanoyl]-2,3-dihydro-1H-indole-2-carboxylate
-
-
ethyl gallate
-
-
fenchyl caffeate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.089 mM
-
fisetin
flavone
galangin
gallic acid
GATA-6
-
inhibits non-steroidal anti-inflammatory drugs-induced transcription of 15-LOX-1 in colorectal cancer cells
-
genistein
genistin
-
IC50: above 0.167 mM
glucocorticoid
-
inhibits induction in monocytes
-
glucosyringic acid
-
IC50: above 0.167 mM
hesperetin
-
IC50: 0.09 mM
interferon-gamma
-
inhibits induction in monocytes
-
iodoacetamide
-
1.0 mM, 30% inhibition
IRKEIKKN
-
33.9% inhibition at 0.25 mM
isotachioside
-
IC50: above 0.167 mM
jaspaquinol
-
IC50: 0.0003 mM
L-carnosine
-
3.6% inhibition at 0.25 mM
linoleic acid
luteolin
methyl 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
-
methyl 3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylate
-
-
methyl gallate
-
-
michellamine B
-
NSC661755, potent but non-selective inhibitor, a natural anti-viral agent
morin
myricetin
N'-(4-bromophenyl)benzohydrazide
28% inhibition
N'-(4-cyanophenyl)benzohydrazide
9% inhibition
N'-(4-methoxyphenyl)benzohydrazide
73% inhibition
N'-(4-methylphenyl)benzohydrazide
93% inhibition, competitive
N'-(4-nitrophenyl)benzohydrazide
17% inhibition
N'-phenylbenzohydrazide
33% inhibition
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N,2-dihydroxybenzamide
-
IC50: 0.057 mM
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
N-(2,5-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(dimethylsulfamoyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(phenylacetyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-[3-(trifluoromethyl)benzene-1-sulfonyl]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
N-(2-chloro-4-fluorophenyl)-4,5-bis(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-fluoro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-5-(trimethylsilyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-phenyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-N-methyl-1H-pyrazole-3-carboxamide
-
N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
-
N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
N-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-chloropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-fluoropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(7-fluoroquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(isoquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-4-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-6-yl)-1H-pyrazole-3-carboxamide
-
N-(tert-butyl)-3-phenyl-6-(p-tolyl)imidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-chlorophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-benzyl-1H-pyrazole-3-carboxamide
-
n-butyl gallate
-
-
N-cyclohexyl-6-(2-fluorophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
-
-
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
-
-
N-phenyl-1H-pyrazole-3-carboxamide
-
n-propyl gallate
-
-
n-tetradecyl gallate
-
-
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
-
-
N-[(5-bromo-8-hydroxy-5,6,7,8-tetrahydroquinolin-7-yl)(thiophen-2-yl)methyl]acetamide
-
N-[2-(1H-indol-3-yl)-1-methylethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(1H-indol-3-yl)ethyl]-2'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00092 mM in the presence of arachidonate, IC50: 0.00046 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-3'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00045 mM in the presence of arachidonate, IC50: 0.00032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(1-methylethyl)biphenyl-4-sulfonamide
-
IC50: 0.00028 mM in the presence of arachidonate, IC50: 0.00014 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(2-methylpropyl)biphenyl-4-sulfonamide
-
IC50: 0.00091 mM in the presence of arachidonate, IC50: 0.00017 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methoxybiphenyl-4-sulfonamide
-
IC50: 0.0015 mM in the presence of arachidonate, IC50: 0.00109 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00047 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
IC50: 0.00042 mM in the presence of arachidonate, IC50: 0.00102 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-propylbenzenesulfonamide
-
IC50: 0.00313 mM in the presence of arachidonate, IC50: 0.0032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-N-methyl-4-pentylbenzenesulfonamide
-
-
N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.0034 mM in the presence of arachidonate, IC50: 0.0042 mM in the presence of linoleic acid
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-dibenzo[b,d]furan-2-yl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(5-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(7-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1-methyl-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-(hydrazinocarbonyl)benzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-bromobenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pyridin-4-ylbenzenesulfonamide
-
-
N-[2-[2-(2,5-dimethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-ethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]biphenyl-4-sulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
-
-
N-[3-(1H-indol-3-yl)propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]biphenyl-4-sulfonamide
-
-
N-[4-(1H-indol-3-yl)butyl]-4-pentylbenzenesulfonamide
-
-
N-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N-[4-fluoro-2-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N1-(2H-1,3-benzodioxol-5-yl)-N-3-(2-chloro-4-fluorophenyl)-1H-pyrazole-1,3-dicarboxamide
-
N1-butyl-N3-(2-chlorophenyl)-N3-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-N1-hexyl-5-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-hexyl-4-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-pentyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chlorophenyl)-N1,N1-dimethyl-1H-pyrazole-1,3-dicarboxamide
-
naringenin
-
IC50: 0.25 mM
neodysidenin
-
natural product from marine sponge Dysidea herbacea from Papua New Guinea, extraction and purification, overview, steady-state inhibition kinetics, competitive mode of inhibition, selective for 12-LO
nor-dihydro-guaiaretic acid
-
-
nordihydroguaiaretic acid
NSC172033
-
a synthetic compound from the NCI library
NSC292213
-
a synthetic compound from the NCI library
NSC617570
-
a synthetic compound from the NCI library
NVPGEIVE
-
65.0% inhibition at 0.25 mM
octyl gallate
-
-
PCMB
-
0.1 mM, 30% inhibition
PD 146 176
-
IC50: 0.00038 mM
PD-146176
-
IC50: 0.00381 mM
PD146176
phenyl[(E)-phenyldiazenyl]methanone
87% inhibition
PKYPVEPFTE
-
74.6% inhibition at 0.25 mM
poly-Lys
-
KKKKKKKK
propyl gallate
-
96% inhibition at 0.05 mM
quercetin
RINKKIEK
-
68.1% inhibition at 0.25 mM, a beta-casein-derived octapeptide
RINKKIPK
-
57.7% inhibition at 0.25 mM
rutin
-
IC50: 1 mM
sarcolobin
-
IC50: 0.06 mM
siRNA
-
SITRINKK
-
65.3% inhibition at 0.25 mM
squalene
-
IC50 is 0.0012 mM
stylosin
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.101 mM
-
tachioside
-
IC50: above 0.167 mM
taxifolin
tephrosin
-
IC50: 0.064 mM
tert-butylhydroxyanisol
-
IC50: 0.16 mM
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
vanillic acid 4-O-beta-D-glucoside
-
IC50: 0.161 mM
villosinol
-
-
[(E)-(4-bromophenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-methoxyphenyl)diazenyl](phenyl)methanone
19% inhibition
[(E)-(4-methylphenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-nitrophenyl)diazenyl](phenyl)methanone
34% inhibition
additional information
-